Close Menu

NEW YORK (GenomeWeb) – Thermo Fisher Scientific said today that it has partnered with Blueprint Medicines to develop and commercialize its Oncomine Dx Target Test as a companion diagnostic for Blueprint's BLU-667 to identify RET fusions in non-small cell lung cancer patients.

Blueprint is currently evaluating BLU-667, a RET kinase inhibitor, in a phase 1 clinical trial to treat patients with RET-driven NSCLC, thyroid cancer, and other advanced solid tumors, and the CDx is supposed to help drive enrollment for the trial.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Mar
21
Sponsored by
Loop Genomics

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

Apr
09
Sponsored by
Sophia Genetics

This webinar will present the utility of a personalized in silico analytical approach for the routine clinical diagnosis of channelopathies and cardiomyopathies. 

Apr
11
Sponsored by
Bionano Genomics

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.